Exclusive interview on ARANOTE study: PSA response with darolutamide plus ADT in patients with mHSPC

Подробнее о видео

UROONCO PCa chief editor Dr. Giancarlo Marra talks to Prof. Fred Saad on the ARANOTE study: Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer (mHSPC).